摘要
目的对乳腺癌患者化疗出现药物性肝损伤(drug-induced liver injury,DILI)原因分析,为相关领域工作者提供借鉴。方法根据药物性肝损伤诊治指南、相关研究报道及Roussel Uclaf因果关系评估法(the roussel uclaf causality assessment method,RUCAM)分析本院1例乳腺癌患者多周期化疗后出现肝损伤的原因,评估可能导致肝损伤的药物。结果该患者DILI不能排除,通过用药时间及RUCAM量表进行关联性评价,发现患者的肝损伤与曲妥珠单抗、紫杉醇及西咪替丁存在相关性。结论 DILI是抗肿瘤药物治疗的剂量限制性毒性。对需多周期化疗的恶性肿瘤患者而言,使用RUCAM量表可较好地鉴别可能的DILI,从而提高肿瘤患者治疗效果。
Objective To analyze the causes of drug-induced liver injury(DILI)in breast cancer patients during chemotherapy,in order to provide reference for workers in related fields.Methods The causes of DILI in a breast cancer patient with multiple chemotherapies were explored and the drugs that may cause liver injury were evaluated according to the guidelines for the diagnosis and treatment of drug-induced liver injury,relevant research publications and the Roussel Uclaf Causality Assessment Method(RUCAM).Results This patient’s DILI could not be excluded.Considering length of drug administration and RUCAM quantitative form,the liver injury showed associations with trastuzumab,paclitaxel and cimetidine.Conclusion DILI is a dose-limiting toxicity of anti-tumor drugs.For patients with malignant tumors that require multiple cycles of chemotherapy,RUCAM quantitative form can distinguish potential DILI and improve treatment outcomes.
作者
沈丽梦
姜孙旻
姚荧
徐银莹
SHEN Limeng;JIANG Sunmin;YAO Ying;XU Yinying(The Affiliated Wuxi Matemity and Child Health Care Hospital of Nanjing Medical University,Wuxi Jiangsu 214002,China)
出处
《中国药物警戒》
2020年第10期703-706,共4页
Chinese Journal of Pharmacovigilance
基金
无锡市卫计委科研青年项目(Q201603)
无锡市卫计委“科教强卫工程”青年医学人才项目(QNRC025)。
